| 51 |
24532820 | Alogliptin: safety, efficacy, and clinical implications. | 2015 Feb |
4 |
| 52 |
25331711 | Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. | 2015 Jan |
1 |
| 53 |
25678772 | Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin. | 2015 |
1 |
| 54 |
25765696 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. | 2015 May 23 |
1 |
| 55 |
25855222 | Alogliptin: a review of its use in patients with type 2 diabetes mellitus. | 2015 May |
1 |
| 56 |
25914541 | Alogliptin benzoate for management of type 2 diabetes. | 2015 |
2 |
| 57 |
25936384 | Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. | 2015 Jun |
1 |
| 58 |
26089691 | Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. | 2015 |
1 |
| 59 |
26103461 | Highly enantioselective synthesis of non-natural aliphatic α-amino acids via asymmetric hydrogenation. | 2015 Jul 28 |
1 |
| 60 |
26218204 | An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. | 2015 Dec |
3 |
| 61 |
26962596 | | 2015 Aug |
1 |
| 62 |
26962605 | | 2015 Aug |
1 |
| 63 |
24225429 | DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy. | 2014 |
2 |
| 64 |
24375601 | Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. | 2014 Jan 15 |
5 |
| 65 |
24400655 | Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. | 2014 Jul |
1 |
| 66 |
24552466 | Relapsing 6q24-related transient neonatal diabetes mellitus successfully treated with a dipeptidyl peptidase-4 inhibitor: a case report. | 2014 Dec |
2 |
| 67 |
24585460 | Separation of alogliptin enantiomers in cyclodextrin-modified capillary electrophoresis: a validated method. | 2014 Oct |
3 |
| 68 |
24646052 | Alogliptin benzoate for the treatment of type 2 diabetes. | 2014 Apr |
1 |
| 69 |
24717767 | Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels. | 2014 Apr 10 |
1 |
| 70 |
24993124 | Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. | 2014 |
3 |
| 71 |
24996141 | Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin. | 2014 Aug 18 |
2 |
| 72 |
25050071 | Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus. | 2014 |
1 |
| 73 |
25158388 | [Alogliptin (Vipidia): a selective DPP-4 inhibitor with a good cardiovascular safety]. | 2014 Jul-Aug |
2 |
| 74 |
25171159 | DPP-4 inhibitors: pharmacological differences and their clinical implications. | 2014 Sep |
1 |
| 75 |
25185672 | Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes. | 2014 |
1 |
| 76 |
25227623 | Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry. | 2014 Sep 16 |
3 |
| 77 |
25283263 | Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect? | 2014 Dec |
1 |
| 78 |
25424968 | A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes. | 2014 Dec |
1 |
| 79 |
27200603 | Assessment of The Economic Value Of Dpp-4 Inhibitor Alogliptin Compared With Sitagliptin, Saxagliptin, And Linagliptin. | 2014 Nov |
1 |
| 80 |
30736193 | Alogliptin for the treatment of Type 2 diabetes. | 2014 Nov |
1 |
| 81 |
23289982 | The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. | 2013 Feb |
3 |
| 82 |
23298374 | Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. | 2013 Jan 9 |
1 |
| 83 |
23323612 | Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect? | 2013 Apr |
1 |
| 84 |
23452780 | Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. | 2013 Mar 1 |
1 |
| 85 |
23489301 | Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. | 2013 Jul |
1 |
| 86 |
23525426 | Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. | 2013 Jan 28 |
1 |
| 87 |
23600363 | Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors. | 2013 Jun |
1 |
| 88 |
23602966 | Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. | 2013 Jun 23 |
5 |
| 89 |
23707531 | Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. | 2013 Sep |
1 |
| 90 |
23861159 | Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. | 2013 Nov |
1 |
| 91 |
23965491 | Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). | 2013 |
1 |
| 92 |
23992602 | Alogliptin after acute coronary syndrome in patients with type 2 diabetes. | 2013 Oct 3 |
2 |
| 93 |
23994324 | Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization. | 2013 Oct |
3 |
| 94 |
24068868 | Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. | 2013 |
2 |
| 95 |
24285765 | Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. | 2013 Nov |
3 |
| 96 |
24376359 | Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγ(null) mice treated with alogliptin. | 2013 |
1 |
| 97 |
22296609 | Alogliptin benzoate for the treatment of type 2 diabetes. | 2012 Mar |
3 |
| 98 |
22419732 | Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. | 2012 May |
1 |
| 99 |
22512582 | Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin. | 2012 Nov |
5 |
| 100 |
22686547 | Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. | 2012 Aug 1 |
1 |